The Promise of Preventive Cancer Vaccines
Pier-Luigi Lollini1, Federica Cavallo2, Patrizia Nanni3
1Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Viale Filopanti 22, Bologna 40126, Italy. pierluigi.lollini@unibo.it.
Abstract:
Years of unsuccessful attempts at fighting established tumors with vaccines have taught us all that they are only able to truly impact patient survival when used in a preventive setting, as would normally be the case for traditional vaccines against infectious diseases. While true primary cancer prevention is still but a long-term goal, secondary and tertiary prevention are already in the clinic and providing encouraging results. A combination of immunopreventive cancer strategies and recently approved checkpoint inhibitors is a further promise of forthcoming successful cancer disease control, but prevention will require a considerable reduction of currently reported toxicities. These considerations summed with the increased understanding of tumor antigens allow space for an optimistic view of the future.
Insights
Cancer vaccines show promise for prevention, not treatment, improving patient survival. Future strategies combining immunoprevention and checkpoint inhibitors require reduced toxicity for effective cancer control.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Established tumor treatment with vaccines has historically yielded limited success.
- Vaccines are most effective in preventive settings, similar to infectious disease vaccines.
- Primary cancer prevention remains a long-term objective, while secondary and tertiary prevention show current clinical promise.
Purpose of the Study:
- To review the current landscape of cancer prevention strategies.
- To explore the potential of combining immunopreventive approaches with checkpoint inhibitors.
- To highlight the need for reduced toxicity in cancer prevention therapies.
Main Methods:
- Literature review of cancer vaccine efficacy and prevention strategies.
- Analysis of current clinical applications of secondary and tertiary cancer prevention.
- Discussion of emerging immunopreventive cancer strategies and their combination with existing therapies.
Main Results:
- Cancer vaccines demonstrate significant impact on patient survival primarily in preventive applications.
- Secondary and tertiary cancer prevention methods are yielding encouraging clinical results.
- Combining immunoprevention with checkpoint inhibitors offers future potential for cancer control.
Conclusions:
- While primary cancer prevention is a future goal, current secondary and tertiary prevention strategies are effective.
- Reducing toxicity in cancer prevention therapies is crucial for successful implementation.
- Advances in understanding tumor antigens support an optimistic outlook for future cancer control through prevention.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
12:43Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Prevention
Some...
Preventive Healthcare Services
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...
